Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)

1. García-Alfonso, P.
2. Benavides, M.
3. Falcó, E.
4. Muñoz, A.
5. Gómez, A.
6. Sastre, J.
7. Rivera, F.
8. Montagut, C.
9. Salgado, M.
10. López-Ladrón, A.
11. López, R.
12. Ruiz de Mena, I.
13. Durán, G.
14. Aranda, E.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1634/THEONCOLOGIST.2018-0316 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus